One Year of Successful Carotid Artery Stenting with the CGuard Device

This registry of daily clinical practice suggests that this specifically designed double-mesh carotid stent is safe and associated with a minimal and acceptable occurrence of neurological events up to 12 months of follow-up.

Un año de éxito de la angioplastia carotídea con el dispositivo CGuard

This double-mesh stent has already been tested, and its short- and long-term efficacy has been proven. However, more recent data have challenged the long-term results, as the device might cause much greater restenosis at 1 year.

Driven by these concerns, a large group of specialist colleagues initiated a multicenter, prospective registry of consecutive patients who had undergone carotid artery stenting with the CGuard device in 20 centers.

The primary endpoint was mortality and stroke at 1 year, and the secondary endpoints included transient ischemic attack, acute myocardial infarction, internal or external carotid intervention, and stent thrombosis.

After one year of follow-up, data were obtained for 726 patients, accounting for 99.04% of the population!

Beyond 30 days, there were 1 minor transient ischemic attack (0.13%), 4 textbook transient ischemic attacks (0.55%), 2 fatal myocardial infarctions (0.27%), and 6 deaths due to a non-cardiac cause (1.10%).

Doppler ultrasound showed internal carotid restenosis in six patients (0.82%); two of them had total occlusion.


Read also: Thrombotic and Bleeding Risk after TAVR: Quick Tips to Stay Up to Date.


No predictors of restenosis, re-occlusion, or events were found. Antiplatelet therapy was sustained for 3 to 6 months.

Conclusion

This real-world registry puts carotid artery stenting to a test once more, this time leveraging the alleged benefits of double-meshed devices, assessing clinical aspects at one year.

Original Title: 1-Year Results From a Prospective Experience on CAS Using the CGuard Stent System-

Reference: Pasqualino Sirignano et al. JACC Cardiovasc Interv. 2021 Sep 13;14(17):1917-1923. doi: 10.1016/j.jcin.2021.05.045.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...